| Title: |
Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study. |
| Authors: |
van Marcke de Lummen, Cédric; Honoré, Natasha; van der Elst, Athénaïs; Beyaert, Simon; Derouane, Françoise; Dumont, Caroline; Aboubakar Nana, Frank; Baurain, Jean-François; Borbath, Ivan; Collard, Philippe; Cornelis, Frank; De Cuyper, Astrid; Duhoux, Francois; Filleul, Bertrand; Galot, Rachel; Gizzi, Marco; Mazzeo, Filomena; Pieters, Thierry; Seront, Emmanuel; Sinapi, Isabelle; Van Den Eynde, Marc; Whenham, Nicolas; Yombi, Jean Cyr; Scohy, Anaïs; van Maanen, Aline; Machiels, Jean-Pascal |
| Contributors: |
UCL - SSS/IREC/FATH - Pôle de Pharmacologie et thérapeutique; UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie; UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie; UCL - SSS/IREC/MBLG - Pôle de Microbiologie médicale; UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie; UCL - SSS/IREC/SLUC - Pôle St.-Luc; UCL - (SLuc) Service de pathologie cardiovasculaire; UCL - (SLuc) Service de microbiologie; UCL - (SLuc) Service de médecine interne générale; UCL - (SLuc) Service de gastro-entérologie; UCL - (SLuc) Service de pneumologie; UCL - (SLuc) Unité d'oncologie médicale; UCL - (SLuc) Centre du cancer |
| Source: |
BMC cancer, Vol. 21, no.1, p. 578 [1-12] (2021) |
| Publisher Information: |
BioMed Central |
| Publication Year: |
2021 |
| Collection: |
DIAL@USL-B (Université Saint-Louis, Bruxelles) |
| Subject Terms: |
Aged; Ambulatory Care; Belgium; COVID-19; Cancer Care Facilities; Cohort Studies; Female; Health Personnel; Humans; Male; Middle Aged; Neoplasms; Risk Factors; SARS-CoV-2; Ambulatory; Non-severe COVID-19; Safety; Systemic anti-cancer treatment |
| Description: |
BACKGROUND: The viral pandemic coronavirus disease 2019 (COVID-19) has disrupted cancer patient management around the world. Most reported data relate to incidence, risk factors, and outcome of severe COVID-19. The safety of systemic anti-cancer therapy in oncology patients with non-severe COVID-19 is an important matter in daily practice. METHODS: ONCOSARS-1 was a single-center, academic observational study. Adult patients with solid tumors treated in the oncology day unit with systemic anti-cancer therapy during the initial phase of the COVID-19 pandemic in Belgium were prospectively included. All patients (n = 363) underwent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) serological testing after the first peak of the pandemic in Belgium. Additionally, 141 of these patients also had a SARS-CoV-2 RT-PCR test during the pandemic. The main objective was to retrospectively determine the safety of systemic cancer treatment, measured by the rate of adverse events according to the Common Terminology Criteria for Adverse Events, in SARS-CoV-2-positive patients compared with SARS-CoV-2-negative patients. RESULTS: Twenty-two (6%) of the 363 eligible patients were positive for SARS-CoV-2 by RT-PCR and/or serology. Of these, three required transient oxygen supplementation, but none required admission to the intensive care unit. Hematotoxicity was the only adverse event more frequently observed in SARS-CoV-2 -positive patients than in SARS-CoV-2-negative patients: 73% vs 35% (P < 0.001). This association remained significant (odds ratio (OR) 4.1, P = 0.009) even after adjusting for performance status and type of systemic treatment. Hematological adverse events led to more treatment delays for the SARS-CoV-2-positive group: 55% vs 20% (P < 0.001). Median duration of treatment interruption was similar between the two groups: 14 and 11 days, respectively. Febrile neutropenia, infections unrelated to COVID-19, and bleeding events occurred at a low rate in the SARS-CoV-2-positive patients. CONCLUSION: ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
boreal:253283; https://hdl.handle.net/2078.1/253283; info:pmid/34016086 |
| DOI: |
10.1186/s12885-021-08349-8 |
| Availability: |
https://hdl.handle.net/2078.1/253283; https://doi.org/10.1186/s12885-021-08349-8 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.C73D455C |
| Database: |
BASE |